Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Genitourinary 2Dermatologic 2Breast 2Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 10Neoplasms 8Neoplasm Metastasis 8Endometrial Neoplasms 6Breast Neoplasms 6Brain Neoplasms 5Unspecified Adult Solid Tumor, Protocol Specific 4Prostatic Neoplasms 4Melanoma 4Lymphoma 4Kidney Neoplasms 4Glioblastoma 4Advanced Cancer 4Uterine Cervical Neoplasms 3Sarcoma 3Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 3Glioma 3Central Nervous System Neoplasms 3Unspecified Childhood Solid Tumor, Protocol Specific 2Solid Tumors 2Small Cell Lung Carcinoma 2Resistant Solid Malignancies 2Pinealoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Lymphoma, Mantle-Cell 2Lung Neoplasms 2

Interventions

Radiotherapy 39pembrolizumab 37Carboplatin 37Cisplatin 34Paclitaxel 26Pemetrexed 24Docetaxel 18Nivolumab 17Magnetic Resonance Spectroscopy 17Gemcitabine 17Bevacizumab 17Specimen Handling 16Cyclophosphamide 15osimertinib 14Radiation 13Irinotecan 13Etoposide 13Erlotinib Hydrochloride 12durvalumab 11Topotecan 10Cetuximab 10Radiosurgery 9Immunoglobulin G 8Fluorouracil 8Everolimus 8Disulfides 8Celecoxib 8fludarabine 7Taxes 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Lung Neoplasms × temsirolimus × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT00659568 2013-05-30

Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
28 enrolled
BreastDermatologicGenitourinaryGynecologicLymphoidOther hematologic neoplasmThoracic

Breast Neoplasms, Burkitt Lymphoma, Carcinoma, Renal Cell, Hodgkin Disease, Immunoblastic Lymphadenopathy, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Endometrial Neoplasms, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡